Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$563.00 USD

563.00
1,024,320

+3.20 (0.57%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $563.06 +0.06 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mark Vickery headshot

Top Research Reports for Disney, Kraft Heinz & Caterpillar

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Kraft Heinz (KHC) and Caterpillar (CAT).

    Zacks Equity Research

    Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

    by Zacks Equity Research

    Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

      Arpita Dutt headshot

      Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs

      by Arpita Dutt

      The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.

        Zacks Equity Research

        Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set

        by Zacks Equity Research

        Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.

          Zacks Equity Research

          Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

          by Zacks Equity Research

          Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Zacks Equity Research

            The Zacks Analyst Blog Highlights: Netflix, Stamps.com, Constellation Brands and Regeneron Pharmaceuticals

            by Zacks Equity Research

            The Zacks Analyst Blog Highlights: Netflix, Stamps.com, Constellation Brands and Regeneron Pharmaceuticals

              Zacks Equity Research

              The Zacks Analyst Blog Highlights: Deere, Alamo Group, Luxfer Holdings and Sonoco Products

              by Zacks Equity Research

              The Zacks Analyst Blog Highlights: Deere, Alamo Group, Luxfer Holdings and Sonoco Products

                Arpita Dutt headshot

                Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

                by Arpita Dutt

                Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.

                  Zacks Equity Research

                  Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention

                  by Zacks Equity Research

                  Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

                    by Arpita Dutt

                    While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

                      Zacks Equity Research

                      Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail

                      by Zacks Equity Research

                      Regeneron Pharmaceuticals (REGN) announced that it will not advance two mid-stage studies evaluating the combination of nesvacumab of Eylea to phase III.

                        Zacks Equity Research

                        Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

                        by Zacks Equity Research

                        Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.

                          Zacks Equity Research

                          Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

                          by Zacks Equity Research

                          Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted

                            by Arpita Dutt

                            While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.

                              Zacks Equity Research

                              Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

                              by Zacks Equity Research

                              Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

                                Ekta Bagri headshot

                                Regeneron (REGN) Q3 Earnings Beat Estimates

                                by Ekta Bagri

                                Regeneron (REGN) beats both earnings and sales estimates in the third quarter driven by an increase in Eylea sales.

                                  Zacks Equity Research

                                  Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?

                                  by Zacks Equity Research

                                  Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.

                                    Zacks Equity Research

                                    What's in the Cards for Adverum (ADVM) This Earnings Season?

                                    by Zacks Equity Research

                                    Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                                      Zacks Equity Research

                                      Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings?

                                      by Zacks Equity Research

                                      Investor focus should be on Eylea's performance and uptake of Dupixent when Regeneron Pharmaceuticals (REGN) reports third-quarter results

                                        Zacks Equity Research

                                        Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak

                                        by Zacks Equity Research

                                        Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.

                                          Zacks Equity Research

                                          Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls

                                          by Zacks Equity Research

                                          Though Amgen (AMGN) beat estimates on both earnings & sales and raised its earnings outlook, shares declined in after-hours trading due to the year-over-year decline in revenues.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

                                            by Arpita Dutt

                                            Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

                                              Zacks Equity Research

                                              Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

                                              by Zacks Equity Research

                                              Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

                                                by Arpita Dutt

                                                With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

                                                  Zacks Equity Research

                                                  Regeneron and Sanofi Get Favorable Ruling Against Amgen

                                                  by Zacks Equity Research

                                                  Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.